Opens in a new tab

Quaternium-73 for Acne: Can a Tiny Dose Make a Difference?

Release time:2026-11-16 | Update time:2026-11-16

Yes—Quaternium-73 demonstrates measurable antimicrobial activity against acne-associated bacteria at parts-per-million concentrations, allowing formulators to target blemish-prone skin at just 0.001% to 0.005%. In in vitro laboratory testing, this yellow crystalline compound inhibits Cutibacterium acnes (C. acnes) at a minimum inhibitory concentration (MIC) as low as 0.00002%, supported by decades of established use in Japanese skincare. Unlike conventional exfoliating acids, Quaternium-73 targets acne-associated bacteria through antimicrobial activity rather than exfoliation. This makes it a complementary option for developing low-dose, multi-active blemish-care formulas, leaving ample room in the base formula for soothing, hydrating, and sebum-balancing ingredients.

What Is Quaternium-73?

Quaternium-73—widely known in the cosmetic industry by the trade name Pionin—is a cationic antimicrobial active engineered for high-potency, low-dose blemish care. Where salicylic acid or benzoyl peroxide address clogged pores through exfoliation or oxidation, Quaternium-73 focuses specifically on controlling acne-related microbial proliferation.

PropertySpecification / Details
INCI NameQuaternium-73
Common / Trade NamePionin (Kankohso No. 201 in Japan)
CAS Number15763-48-1
AppearanceFine yellow crystalline powder
Ionic NatureCationic (positively charged)
Primary FunctionTargeted antimicrobial support
Typical Use Level0.001% – 0.005%

Quaternium-73 has a long history of use in Japan. Listed as Kankohso No. 201 in the Japanese cosmetic ingredient standards established in 1967, it also has regulatory precedent as an active ingredient in Japanese quasi-drug products intended to prevent acne, as outlined in NAGASE’s official PIONIN™ product documentation. While regulatory classifications differ outside Japan, this multi-decade track record gives global formulators a well-characterized benchmark for low-dose antimicrobial skincare.

How It Targets Acne-Related Bacteria

Blemish development is driven by four overlapping factors: excess sebum production, follicular hyperkeratinization, localized inflammation, and microbial imbalance involving Cutibacterium acnes (formerly Propionibacterium acnes).

Quaternium-73 addresses the microbial pathway through charge interaction. Because the molecule carries a positive (cationic) charge, it is electrostatically attracted to negatively charged bacterial cell envelopes. Upon contact, it disrupts cell membrane integrity and interferes with normal metabolic survival, inhibiting bacterial growth at trace concentrations.

How Quaternium-73 Works Against Acne-Related Bacteria
Conceptual illustration of Quaternium-73 interacting with acne-associated bacterial cell membranes

In standard in vitro microbiological assays, Quaternium-73 exhibits an MIC against C. acnes as low as 0.00002% (0.2 ppm). To put that figure in perspective, a typical commercial starting dose of 0.002% is 100 times higher than the baseline laboratory inhibition threshold—helping account for real-world formulation variables such as surfactant binding, rinse-off contact time, and skin surface sebum. Because its mechanism does not depend on desquamation or acidic pH, it offers a distinct functional pathway compared to traditional keratolytic acids.

What Does the Research Actually Show?

When evaluating Quaternium-73 for commercial product development, R&D teams should distinguish between standalone in vitro microbiological data, multi-active human studies, and emerging delivery-system research.

Human Study on Dissolving Microneedle Patches (2022)

A 2022 clinical study published in the Journal of Cosmetic Dermatology evaluated dissolving anti-acne microneedle patches containing Quaternium-73 alongside complementary anti-blemish actives across 30 subjects with visible facial acne. Over the 28-day study period, investigators recorded:

  • 12.34% reduction in acne lesion volume after 3 days
  • Additional 10.01% reduction in acne volume after 7 days
  • 5.88% decrease in measured skin melanin index at Day 28
  • Zero adverse skin reactions reported throughout the trial

Because the tested patch combined multiple active ingredients within a physical microneedle delivery matrix, the 12.34% Day-3 reduction reflects the performance of the complete patch system rather than Quaternium-73 acting alone in a conventional emulsion or serum.

Preclinical Combination Delivery Research (2025)

More recently, a 2025 study in Microsystems & Nanoengineering investigated a dual-phase dissolving microneedle system engineered to co-deliver PIONIN, salicylic acid, and dipotassium glycyrrhizinate. The researchers demonstrated that pairing a poorly water-soluble antimicrobial with water-soluble soothing and keratolytic agents in a structured delivery carrier achieved strong antibacterial activity against acne-associated bacteria and favorable preclinical anti-acne outcomes.

Summary of Supporting Evidence

Evidence TypeKey FindingPractical Scope for Formulators
In Vitro MIC TestingInhibits C. acnes at concentrations as low as 0.00002%Establishes baseline antimicrobial potency at trace doses
Japanese Regulatory HistoryListed in Japan’s 1967 cosmetic ingredient standards (Kankohso No. 201) with quasi-drug precedentDemonstrates long-term commercial use in regulated anti-acne formulas
2022 Human Patch Study12.34% acne volume reduction at Day 3 in a 30-subject trialValidates multi-active combination patches; does not isolate single-ingredient efficacy
2025 Delivery ResearchCo-delivery of Pionin, salicylic acid, and dipotassium glycyrrhizinateDemonstrates the feasibility of delivering Quaternium-73 alongside complementary actives in an advanced microneedle system
Quaternium-73 for Acne What Does the Research Show
Overview of laboratory, human combination-formula and preclinical evidence related to Quaternium-73

If you are mapping out bench trials or reviewing technical specifications for an upcoming blemish-care project, explore the full grade details on our NOYAIN Quaternium-73 product page.

Where Quaternium-73 Fits in Skincare Formulations

For product developers, Quaternium-73 is rarely positioned as a standalone active. Instead, it serves as a low-dose antimicrobial component that complements daily acne-prone and oily-skin formulas without adding sensory heaviness.

Product FormatFormulation Role & Positioning
Lightweight Serums & TonersDaily antimicrobial maintenance in fast-absorbing, non-comedogenic bases
Targeted Spot GelsConcentrated localized blemish care paired with soothing or keratolytic actives
Facial CleansersAntimicrobial support in rinse-off gels and foams using compatible surfactant systems
Hydrocolloid & Microneedle PatchesHigh-value targeted blemish patches combining physical protection with active delivery
Oil-Control Gel-CreamsLightweight moisturizers designed for oily and blemish-prone skin
Quaternium-73 in Skincare From Cleansers to Acne Patches
Serum, spot gel, facial cleanser and microneedle patch concepts for acne-prone skincare

Formulation Guidelines: Dosage, Solubility, and Compatibility

Working at parts-per-million levels keeps raw material cost-in-use efficient, but Quaternium-73 requires deliberate processing to ensure uniform dispersion and long-term stability.

Recommended Use Level and Premixing

For commercial formulation development with NOYAIN Quaternium-73, we recommend a starting dosage range of 0.001% to 0.005%, adjusted according to target-market regulations and finished-product safety testing.

Because Quaternium-73 has poor solubility in water, adding the crystalline powder directly into the main aqueous phase often leads to incomplete dissolution or recrystallization. Instead, pre-dissolve the powder in a suitable solvent carrier—such as Butylene Glycol, Propylene Glycol, 1,2-Pentanediol, or Ethanol—with gentle stirring before incorporating the premix into your batch.

Critical Stability and Charge Checks

  • Cationic–Anionic Compatibility: Because Quaternium-73 is cationic, certain anionic ingredients—such as specific anionic surfactants or anionic rheology modifiers—may present compatibility challenges depending on concentration and formulation structure. Overall compatibility depends on the complete formulation, so bench testing is recommended to confirm solubility, clarity, and stability.
  • Light and Color Stability: Quaternium-73 is naturally yellow. Even at 0.001–0.005%, prolonged UV exposure can trigger slight color shift or potency loss—validate stability under accelerated light exposure and specify UV-filtering or opaque packaging where needed.
  • Preservation System Integrity: Do not rely on 0.001–0.005% Quaternium-73 to replace a broad-spectrum preservative system; always verify microbiological protection via standard Preservative Efficacy Testing (PET).

Compatible Actives for Multi-Mechanism Formulas

Modern acne-care formulas often combine multiple mechanisms to address blemish-prone skin. Depending on your formulation goals, Quaternium-73 can be evaluated as a potential pairing alongside:

  • Niacinamide: Shares a compatible near-neutral pH window (pH 5.5–7.0), offering a direction that pairs antimicrobial support with sebum regulation and barrier care.
  • Salicylic Acid: Combines pore-clearing exfoliation with antimicrobial support. For water-dominant formulas where free salicylic acid poses solubility challenges, formulators can also evaluate NA40, NOYAIN’s salicylic acid–methyl-cyclodextrin complex.
  • Allantoin and Panthenol: Non-ionic soothing and hydrating ingredients such as Allantoin can help support skin comfort alongside antimicrobial care.
  • Zinc PCA: Incorporating Zinc PCA offers a complementary direction for oily-skin and sebum-control positioning.

Each combination should be verified through bench stability and compatibility testing in the target base.

Safety Profile and Global Regulatory Context

Quaternium-73 is used at low concentrations in skincare formulations. Its safety should be assessed within the finished product, taking into account the intended use level, exposure, and complete formula. According to the EWG Skin Deep ingredient profile for Quaternium-73, the compound receives low hazard scores across key categories such as allergies and immunotoxicity, while noting that publicly indexed data remain limited.

From a compliance standpoint, brand owners must align product claims with regional frameworks. While Quaternium-73 has established quasi-drug precedent in Japan, cosmetic products marketed in the United States, European Union, or ASEAN markets cannot make drug-level acne-treatment claims based solely on Japanese regulatory history. Brands should verify local ingredient inventories, concentration limits, and finished-product toxicological safety assessments prior to commercial launch.

Evaluating Quaternium-73 for Commercial Production

Because Quaternium-73 is dosed at fractions of a percent, batch-to-batch purity and consistency play an important role in dissolution and formulation reliability. Before selecting a raw material supplier, R&D and procurement teams should review HPLC assay specifications, batch Certificate of Analysis (COA) data, solubility guidance, and available technical documentation.

NOYAIN supplies high-purity Quaternium-73 (≥99.0% by HPLC) for skincare brands, R&D formulators, OEM/ODM manufacturers, and ingredient distributors. Our team can provide available technical documentation and sample support to help you evaluate the ingredient in your own formulations.

Final Thoughts

Yes. Quaternium-73 demonstrates that powerful antimicrobial activity doesn’t require a high ingredient concentration. Backed by trace-level in vitro activity against C. acnes, decades of established Japanese skincare applications, and versatile compatibility across gels, serums, cleansers, and patches, it gives formulators a focused tool for flexible blemish-care product development. Starting with high-purity NOYAIN Quaternium-73 (≥99% HPLC) and verifying solubility and stability in your finished formula allows brands to turn a micro-dose active into a technically sound acne-care solution.

Disclaimer

The content of this blog is for informational purposes only and does not constitute any guarantee. As an upstream supplier of cosmetic raw materials, Noyain focuses on bulk wholesale of raw materials and can provide free samples for testing. This article cannot replace professional testing. Customers are solely responsible for the regulatory compliance and safety of their product applications, formulations, and efficacy claims. For specifications, technical documents, or quotations, please contact our sales team.

Share
Popular ingredients
PDRN / Sodium DNA
A repair-focused active ingredient for premium skincare formulas, suitable for soothing, post-acne care, anti-aging and skin renewal concepts.
Request PDRN SampleView Product Details
Need Help Choosing Cosmetic Actives?
Tell us your formula type, target claim and market. Our team can recommend suitable ingredients and sample options.
Contact Technical Team
We’ll get in touch with you within 24 hours. Please check your email and WhatsApp messages.

Enter your Phone & business email to download our 2026 Catalog & Technical Dossier
Please fill out the form to receive the file for free
联系我们